These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Phase II trial of 4'-deoxydoxorubicin in patients with advanced breast cancer.
    Author: Leitner SP, Casper ES, Hakes TB, Kaufman RJ, Winn RJ, Scoppetuolo M, Raymond V, Geller NL, Young CW.
    Journal: Cancer Treat Rep; 1985 Nov; 69(11):1319-20. PubMed ID: 4092194.
    Abstract:
    4'Deoxydoxorubicin (25 mg/m2 iv every 3 weeks) was evaluated in 20 patients with advanced breast cancer. The patients had good performance status and had not been heavily pretreated. Although all patients experienced leukopenia, no major therapeutic responses were observed. Nonhematologic toxicity was mild. Further evaluation of 4'-deoxydoxorubicin at this dose and schedule is not warranted in patients with advanced breast cancer.
    [Abstract] [Full Text] [Related] [New Search]